These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34326317)

  • 21. Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study.
    Parai D; Choudhary HR; Dash GC; Behera S; Mishra N; Pattnaik D; Raghav SK; Mishra SK; Sahoo SK; Swain A; Mohapatra I; Pattnaik M; Moharana A; Jena SR; Praharaj I; Subhadra S; Kanungo S; Bhattacharya D; Pati S
    Front Microbiol; 2022; 13():942659. PubMed ID: 36016787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose.
    Rossi AH; Ojeda DS; Varese A; Sanchez L; Gonzalez Lopez Ledesma MM; Mazzitelli I; Alvarez Juliá A; Oviedo Rouco S; Pallarés HM; Costa Navarro GS; Rasetto NB; Garcia CI; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Sosa S; Bianchimano L; Rios AS; Treffinger Cienfuegos MS; Caramelo JJ; Longueira Y; Laufer N; Alvarez DE; Carradori J; Pedrozza D; Rima A; Echegoyen C; Ercole R; Gelpi P; Marchetti S; Zubieta M; Docena G; Kreplak N; Yanovsky M; Geffner J; Pifano M; Gamarnik AV
    Cell Rep Med; 2021 Aug; 2(8):100359. PubMed ID: 34308389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination.
    Shen CF; Yen CL; Fu YC; Cheng CM; Shen TC; Chang PD; Cheng KH; Liu CC; Chang YT; Chen PL; Ko WC; Shieh CC
    Front Immunol; 2022; 13():807454. PubMed ID: 35145520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
    Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
    Front Immunol; 2021; 12():795741. PubMed ID: 34925381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
    Wall EC; Wu M; Harvey R; Kelly G; Warchal S; Sawyer C; Daniels R; Adams L; Hobson P; Hatipoglu E; Ngai Y; Hussain S; Ambrose K; Hindmarsh S; Beale R; Riddell A; Gamblin S; Howell M; Kassiotis G; Libri V; Williams B; Swanton C; Gandhi S; Bauer DL
    Lancet; 2021 Jul; 398(10296):207-209. PubMed ID: 34197809
    [No Abstract]   [Full Text] [Related]  

  • 32. Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects.
    Gillot C; Favresse J; Maloteau V; Dogné JM; Douxfils J
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
    Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
    Front Immunol; 2021; 12():778679. PubMed ID: 34868051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals.
    Hirotsu Y; Amemiya K; Sugiura H; Shinohara M; Takatori M; Mochizuki H; Omata M
    Front Immunol; 2021; 12():722766. PubMed ID: 34512649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.
    Song S; Zhou B; Cheng L; Liu W; Fan Q; Ge X; Peng H; Fu YX; Ju B; Zhang Z
    Virol J; 2022 Jan; 19(1):2. PubMed ID: 34983583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
    Favresse J; Gillot C; Di Chiaro L; Eucher C; Elsen M; Van Eeckhoudt S; David C; Morimont L; Dogné JM; Douxfils J
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers.
    Chau NVV; Nguyet LA; Truong NT; Toan LM; Dung NT; Hung LM; Nhan MT; Man DNH; Ngoc NM; Thao HP; Tu TNH; Mai HK; Hung DT; Ny NTH; Thanh LK; Anh NT; Hong NTT; Nhu LNT; Yen LM; Choisy M; Thanh TT; Thwaites G; Tan LV;
    Am J Trop Med Hyg; 2022 Jan; 106(2):556-561. PubMed ID: 34996048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka.
    Jeewandara C; Aberathna IS; Danasekara S; Gomes L; Fernando S; Guruge D; Ranasinghe T; Gunasekera B; Kamaladasa A; Kuruppu H; Somathilake G; Jayamali J; Jayathilaka D; Wijayatilake HDK; Pushpakumara PD; Harvie M; Nimasha T; de Silva SDG; Wijayamuni R; Schimanski L; Rijal P; Tan J; Townsend A; Ogg GS; Malavige GN
    Immunology; 2022 Oct; 167(2):263-274. PubMed ID: 35751563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.